五种不同中药经典方剂影响各型慢性阻塞性肺疾病大鼠气道病理改变的特点

目的：通过观察慢性阻塞性肺疾病大鼠治疗前后气道病理的改变，分析中医药治疗慢性阻塞性肺疾病的可能机制。方法：实验于2005-04／2005-10山东中医药大学附属医院中心实验室进行。①健康雄性SPF级Wistar大鼠264只，随机数字表法分为以下11组：空白对照组，寒痰蕴肺模型组和治疗组，痰热阻肺模型组和治疗组，肺气虚模型组和治疗组，脾气虚模型组和治疗组，肾气虚模型组和治疗组，每组24只。采用改良烟熏加气管滴加脂多糖方法复制慢性阻塞性肺疾病模型，并根据分型，分别给予不同干预，进行二次造模。②第30天起各治疗组分别灌服相应证型的预治疗中药合剂，连续14d。寒痰蕴肺治疗组灌服小青龙汤煎剂（麻黄9g，桂枝6g，白芍9g，干姜3g，五昧子3g，半夏9g，甘草6g，细辛3g，水煎浓缩为浓度0．6g／mL的浓缩液），痰热阻肺治疗组大鼠灌服麻杏石甘汤煎剂（麻黄5g，杏仁9g，甘草6g，石膏18g，水煎浓缩为浓度0．475g／mL的浓缩液），肺气虚治疗组灌服玉屏风散煎剂（防风3g，黄芪3g，白术6g，水煎浓缩为浓度0．15g/mL的浓缩液），脾气虚治疗组灌服六君子汤煎剂（人参9g，白术9g，茯苓9g，炙甘草6g，半夏12g，陈皮9g，水煎浓缩为浓度0．675g／mL的浓缩液），肾气虚治疗组灌服人参蛤蚧散煎剂（蛤蚧6g，杏仁15g，甘草15g，人参6g，茯苓6g，贝母6g，桑白皮6g，知母6g，除蛤蚧外其他药物水煎浓缩为浓度0．75g/mL的浓缩液，蛤蚧研末兑入），2mL／d，相当于成人剂量的7．5倍（饮片由山东中医药大学附属医院中药房提供）。模型组大鼠每天给与2mL生理盐水灌胃。空白对照组不做任何干预，相同室内环境下自由饮食饮水。③光镜下观察大鼠小气道病理改变，电镜下观察大鼠气管纤毛的变化，并按照小气道病变评估方法和标准进行分析描述。结果：实验过程中，各造模组均有大鼠死亡，最终进入结果分析242只。①正常对照组中、小支气管黏膜上皮细胞排列整齐，肺泡结构连续，肺泡壁完整，且未见明显渗出。模型组气道黏膜充血水肿，上皮细胞变性坏死糜烂脱落，肺内细支气管、终末细支气管管腔及周围表现出不同程度的慢性炎性细胞浸润，管壁周围平滑肌和纤维细胞增生、断裂；肺泡管、肺泡囊及肺泡明显扩大，间隔变薄、断裂，肺泡扩大融合；小动脉血管壁增厚，平滑肌增生，管腔变小，周围炎性细胞浸润。②光镜、电镜下观察治疗组与模型组相比纤毛粘连倒伏、上皮细胞变性坏死以及炎细胞浸润等现象表现均明显减轻，肺大泡数量减少。结论：各经典方剂通过辨证论治均可以缓解大鼠肺内细支气管、终末细支气管管腔及周围表现炎性细胞浸润及分泌物阻塞，恢复纤毛粘连、倒伏、脱落，改善气道高反应性和气道重塑，对于慢性阻塞性肺疾病气道的修复和炎症的缓解作用。     

益肺健脾中药改善慢性阻塞性肺疾病患者肺功能及营养状况

目的：探讨益肺健脾中药对慢性阻塞性肺疾病患者肺功能和营养状况的调节作用.方法：[1]选择2000-01/10呼吸科门诊就诊的缓解期慢性阻塞性肺疾病患者20例,男18例,女2例.均自愿参加各项指标检测.按理想体质量百分比将患者分为2组：理想体质量百分比＜90%为营养不良组8例,理想体质量百分比≥90%为营养正常组12例.根据病情程度将患者分为3组：第1秒用力呼气量占预计值百分比≥70%为轻度组3例,50%＜第1秒用力呼气量占预计值百分比≤69%为中度组10例,第1秒用力呼气量占预计值百分比≤50%为重度组7例.[2]给予慢性阻塞性肺疾病患者益肺健脾中药（黄芪30 g,党参15 g,白术15 g,茯苓15 g,防风10 g,半夏15 g,陈皮10 g,地龙8 g,款冬花10 g,甘草10 g.偏于中阳虚者加干姜6g;肺金郁热者加黄芩10g;痰浊偏甚者加白芥子10 g;气逆喘甚者加苏子10 g,旋复花10 g）,1剂/d,水煎取汁,分2次服用,疗程8周.[3]用肺功能仪测定第1秒用力呼气量占预计值百分比、第1秒用力呼气量占用力肺活量百分比.根据受试者身高、年龄查得理想体质量,求出实际体质量占理想体质量百分比.[4]计量结果差异性比较采用t检验.结果：比较不同病情程度患者营养状况和肺功能时轻度组患者样本例数少（3例）不纳入结果分析.[1]第1秒用力呼气量占预计值百分比、第1秒用力呼气量占用力肺活量百分比和理想体质量百分比：益肺健脾中药治疗后明显高于治疗前[（63.6&;#177;14.7）%,（61.5&;#177;6.6）%,（96.2&;#177;13.8）%;（55.2&;#177;14.8）%,（57.5&;#177;5.9）%,（94.4&;#177;14.6）%,t=5.9,5.8,7.8,P＜0.01];营养不良组和营养正常组治疗后明显高于治疗前（t=2.7～9.6,P＜0.05～0.01）;中度组和重度组治疗后明显高于治疗前（t=2.5～6.7,P＜0.05～0.01）.[2]理想体质量百分比：营养正常组治疗前和治疗后明显高于营养不良组治疗前和治疗后（t=6.7,6.7,P＜0.01）.[3]第1秒用力呼气量占预计值百分比和第1秒用力呼气量占用力肺活量百分比：重度组治疗前和治疗后明显低于中度组治疗前和治疗后（t=3.6～7.5,P＜0.01）.结论：益肺健脾中药可减善慢性阻塞性肺疾病患者肺功能和营养状态.     

益肺健脾中药改善慢性阻塞性肺疾病患者肺功能及营养状况

目的:探讨益肺健脾中药对慢性阻塞性肺疾病患者肺功能和营养状况的调节作用。方法:①选择2000-01/10呼吸科门诊就诊的缓解期慢性阻塞性肺疾病患者20例,男18例,女2例。均自愿参加各项指标检测。按理想体质量百分比将患者分为2组:理想体质量百分比<90%为营养不良组8例,理想体质量百分比≥90%为营养正常组12例。根据病情程度将患者分为3组:第1秒用力呼气量占预计值百分比≥70%为轻度组3例,50%<第1秒用力呼气量占预计值百分比≤69%为中度组10例,第1秒用力呼气量占预计值百分比≤50%为重度组7例。②给予慢性阻塞性肺疾病患者益肺健脾中药(黄芪30g,党参15g,白术15g,茯苓15g,防风10g,半夏15g,陈皮10g,地龙8g,款冬花10g,甘草10g。偏于中阳虚者加干姜6g;肺金郁热者加黄芩10g;痰浊偏甚者加白芥子10g;气逆喘甚者加苏子10g,旋复花10g),1剂/d,水煎取汁,分2次服用,疗程8周。③用肺功能仪测定第1秒用力呼气量占预计值百分比、第1秒用力呼气量占用力肺活量百分比。根据受试者身高、年龄查得理想体质量,求出实际体质量占理想体质量百分比。④计量结果差异性比较采用t检验。结果:比较不同病情程度患者营养状况和肺功能时轻度组患者样本例数少(3例)不纳入结果分析。①第1秒用力呼气量占预计值百分比、第1秒用力呼气量占用力肺活量百分比和理想体质量百分比:益肺健脾中药治疗后明显高于治疗前犤(63.6±14.7)%,(61.5±6.6)%,(96.2±13.8)%;(55.2±14.8)%,(57.5±5.9)%,(94.4±14.6)%,t=5.9,5.8,7.8,P<0.01犦;营养不良组和营养正常组治疗后明显高于治疗前(t=2.7～9.6,P<0.05～0.01);中度组和重度组治疗后明显高于治疗前(t=2.5～6.7,P<0.05～0.01)。②理想体质量百分比:营养正常组治疗前和治疗后明显高于营养不良组治疗前和治疗后(t=6.7,6.7,P<0.01)。③第1秒用力呼气量占预计值百分比和第1秒用力呼气量占用力肺活量百分比:重度组治疗前和治疗后明显低于中度组治疗前和治疗后(t=3.6～7.5,P<0.01)。结论:益肺健脾中药可减善慢性阻塞性肺疾病患者肺功能和营养状态。     

补虚汤合参蛤散治疗肺肾气虚型慢性阻塞性肺疾病的疗效观察

慢性阻塞性肺疾病(COPD)是一种以气流受限为特征的疾病,属于中医咳、喘、哮、肺胀等病证范畴.我国15岁以上人口中COPD的患病率约为3％.40岁以上人口患病率约为9％.COPD居世界人类致死原因第4位.笔者采用补虚汤合参蛤散治疗肺肾气虚型慢性阻塞性肺疾病取得满意疗效,现报道如下.     

黄芪对慢性阻塞性肺疾病模型大鼠气道重塑的影响

目的：探讨黄芪对慢性阻塞性肺疾病（COPD）模型大鼠气道重塑的影响。方法：采用熏吸香烟加气管内注射脂多糖的方法建立大鼠COPD模型，测定黏膜下炎症细胞、肺小动脉、支气管壁的变化。结果：治疗组支气管黏膜下炎症细胞数较模型组明显减少（P〈0.01）；治疗组肺小动脉管壁厚度明显较模型组薄，差异有显著性（P〈0.05）；治疗组细支气管平滑肌厚度亦明显较模型组薄，差异有显著性（P〈0.05）。结论：黄芪能够减缓COPD患者的气道重构，延缓或阻止COPD疾病的发展。     

多因素慢性阻塞性肺疾病大鼠模型的建立

目的　寻求建立慢性阻塞性肺疾病(COPD)大鼠模型的新方法。方法　以熏烟、寒冷刺激4周,结合两次气管内注入脂多糖的多因素刺激制作COPD大鼠模型。结果　COPD模型组大鼠体重增幅下降(P<0 .0 1) ,呼吸频率高于正常对照组(P <0 .0 1) ,而温水游泳时间则低于正常对照组(P <0 .0 1) ,0 .3s用力呼气容积占用力肺活量比、呼气峰值流速、呼气中期流速较正常对照组降低(P <0 .0 1) ,吸气阻力、呼气阻力,较正常对照组增高(P <0 .0 1) ;COPD模型组大鼠气管、支气管及肺组织有慢性炎症及阻塞性肺气肿的特征性病理改变。结论　采用熏烟、寒冷和脂多糖多因素复合刺激的方法,可成功制备COPD大鼠模型,该模型不仅病理形态学和肺功能的改变与人类COPD类似,而且在整体状况和运动能力方面的变化与人类COPD的临床病程和表现更接近。     

慢性阻塞性肺疾病患者的护理

慢性阻塞性肺疾病(COPD)是一种常见的疾病,患病人数多,病死率高,社会经济负担重,治疗和护理工作至关重要,现将我科收治的慢性阻塞性肺疾病患者的护理体会报告如下。1临床资料1.1一般资料2005-08～2007-05住院的COPD患者135例,男89例,女46例,年龄48～92(平均69.6)岁,中位年龄71岁。均符合慢性阻塞性肺疾病的诊断标准。1.2方法均予有效抗感染、氧疗、预防和控制心力衰竭、纠正酸碱平衡失调及电解质紊乱、控制心律失常、对症治疗及进行有针对性的细致周到的护理等。1.3结果124例经治疗病情好转出院,有效率91.9%。2护理2.1帮助患者戒烟戒烟…     

无症状慢性阻塞性肺疾病患者特点分析

目的了解无症状慢性阻塞性肺疾病(COPD)患者的临床特点。方法对在2010年1月至2011年12月在天津市职业病防治院健康体检的36 231人次进行调查,筛检出1042例COPD患者,遂进行问诊、体检,调查问卷并进行肺功能检查。结果无症状COPD患者432例,总患病率为1.19%;有症状COPD患者610例,总患病率为1.68%。无症状组和有症状组患者性别、年龄、职业、婚姻状况、受教育程度和吸烟情况比较差异均无统计学意义(P>0.05)。肺功能检测显示,无症状组第一秒用力呼气容积(FEV1)、第一秒用力呼气容积占预计值百分比(FEV1占预计值%)与有症状组比较,差异均有统计学意义(P<0.05)。结论早期肺功能受损不太严重时临床症状不明显,因而造成COPD的漏诊和对疾病危害的低估,而早期COPD的诊断需要检测肺功能。     

中药雾化吸入治疗慢性阻塞性肺疾病的观察及护理

为探讨中药红花注射液加鱼腥草注射液雾化吸入对慢性阻塞性肺疾病(COPD)患者的抗凝消炎作用 ,对COPD 12 2例进行了临床观察及护理 ,取得了满意的效果 ,现报告如下。1　资料与方法1 1　临床资料　 1999年至 2 0 0 2年在我院住院COPD患者 2 0 0例 ,随机分为治疗组和对照组。临床资料见表 1。病例选择中医诊断标准参考中药新药临床研究指导原则[1] ,西医诊断、分级、分期均依据中华医学会呼吸病分会制定的标准[2 ] 。表 1　两组患者一般资料比较 (x±s)组别n性　别男女年　龄(岁 )病程(t/a)病情程度轻中重病情分期急重期稳定期治疗组 1 2 …     

氧疗护理对老年慢性阻塞性肺疾病的影响

目的:探讨氧疗对老年慢性阻塞性肺疾病(CDPD)患者的影响。方法:将40例慢性阻塞性肺部疾病患者随机分成观察组和对照组。观察组患者予坚持氧气吸入,每天吸氧时间不少于15 h。对照组患者予每天未能坚持氧气吸入。记录用氧效果。结果:两组的总有效率(有效率+显效率)无统计学差异(P0.05),而观察组显效率明显高于对照组,两组间有统计学差异(P0.05)。结论:长期氧疗对老年慢性阻塞性肺疾病效果明显,有利于患者的康复。     

慢性阻塞性肺病传统康复运动处方的制定

目的制定传统中医康复锻炼的规范化运动处方。方法选择第一秒用力呼气容积(FEV1)/用力肺活量(FVC)＜70%,且30%＜FEV．占预计值的百分比(FEV1%)＜80%的慢性阻塞性肺病(COPD)稳定期患者90例(最后完成的有85例),按入组先后随机分为对照组、传统中医锻炼组(中医组)和传统中医锻炼运动处方组(处方组),后2组进行为期8周的运动训练,处方组训练内容为按规范化运动处方要求制定的中医养生呼吸操。治疗前、后进行运动能力、呼吸困难评定。结果锻炼后6 min步行距离(6MWD)中医组从(337．68±59．18)m增加至(386．14±76．71)m,处方组从(348．00±55．94)m增加至(425．17±53．22)m,Borg计分中医组从(3．14±1．94)分降至(2．32±1．25)分,处方组从(3．45±1．84)分降至(1．72±0．70)分,差异均有统计学意义(P≤0．001),且处方组的变化较中医组更为明显。结论中医养生锻炼运动处方简单易行,能改善缓解期COPD患者的运动能力,减轻呼吸困难程度,且较传统中医康复锻炼方法更有效,具有可行性。     

慢性阻塞性肺疾病患者实施延续护理的效果评价

目的 观察延续护理在慢性阻塞性肺疾病患者的应用效果。 方法 选取2015年6~12月收治的慢性阻塞性肺疾病患者41例为常规组,实施常规护理;选取2016年1~7月收治的慢性阻塞性肺疾病患者43例为观察组,在常规护理基础上实施延续护理。观察2组患者出院时及出院3个月后的肺功能、6min步行距离、慢性阻塞性肺疾病评估测试量表评分(COPD assessment test, CAT)及生存质量。 结果 出院3个月后,观察组用力肺活量(FVC)、第1秒用力呼气容积(FEV1)和第1秒用力呼气容积/用力肺活量(FEV1/FVC)、6min步行距离、日常生活能力和社会活动情况的评分均高于常规组,CAT评分、抑郁心理情况和焦虑心理症状评分明显低于常规组。 结论 对慢性阻塞性肺疾病患者实施延续护理可缓解患者的临床症状,改善患者的肺功能,提升患者的生存质量。     

慢性阻塞性肺疾病患者住院期间中医药需求情况的调查

目的 了解慢性阻塞性肺疾病(COPD)患者住院期间对中医药治疗需求的状况.方法 回顾2008～2009年因COPD住院的患者资料,根据出院时中草药费用,分析住院期间对中医药需求的状况.结果 在1676例COPD住院患者中,根据住院期间显示有中(草)药费用的有482例,占28.7％;女性中医药需求高于男性,男性占27.95％,女性占32.5％,56～75岁年龄段患者,经X2检验,差异有统计学意义(P＜0.05);住院≤7 d与＞30d的患者比较,＞30 d的患者需求中药人数多于≤7 d的人数x2=66.801,P=0.000;住院1次与≥5次的患者比较,≥5次住院的患者需求中药高于1次住院患者,x2=39.625,P=0.000.结论 建议护理人员关心对中医药治疗有需求的COPD患者,为他们提供中医护理服务.     

辛伐他汀对慢性阻塞性肺疾病患者全身性炎症反应的影响

Objective To investigate the influence of simvastatin on inflammatory indices in nasal lavage,sputum and blood and clinical index in patients with chronic obstructive pulmonary diseases (COPD). Methods Thirty-seven stable COPD patients were randomly divided into simvastatin-treatment group (n=17),orally given simvastatin tablets for 4 weeks in addition to basic therapy,40 mg,qd) and control group (n=20),given usual med-ication). Total cell counts,percentage of leukocytes (N%) and levels of interleukin IL-8,IL-6 in nasal lavage and sputum at pre-post-treatment were compared;Serum C-reactive protein (CRP),total cholesterol (TC),low-density lipoprotein-cholesterol (LDL-C) as well as IL-8,IL-6 concentrations were measured,the variation of lung function,Sino-Nasal Outcome Test 20(SNOT-20) and St George's Respiratory Questionnaire(SGRQ) score were analyzed. Results After the treatment,the nasal lavage and sputum total cell counts,N%,IL-8 and IL-6 levels[nasal lavage: (0.7±0.3)×107/L,(41.1±10.9)%,(105.8±74.5) ng/L,(3.8±1.6) ng/L;sputum: (0.8±0.3)×109/L,(56.6±9.6) %,(2565.5±831.9) ng/L,(109.8±42.3) ng/L] dropped slightly in the simvastatin group com-pared with that at pretreatment [nasal lavage: (0.8±0.3)×107/L,(43.2±10.8) %,(107.6±86.3) ng/L,(4.1±1.9)ng/L;sputum: (0.8±0.3)×109/L,(58.1±9.3)% ,(2659.4±885.2) ng/L,(111.8±46.6) ng/L] (P>0.05) ;There were significant decreases in serum CRP [(4.3±3.7) mg/L vs (2.6±1.8) mg/L],IL-6 [(4.8±2.0)ng/L vs(4.7±1.9)ng/L] ,TC[(4.2±1.0) mmol/L vs(3.7±0.8)mmol/L] ,LDL-C[(2.4±0.5) mmol/L vs (2.2±0.5)mmol/L] (P>0.05) ;IL-8 concentrations in serum were lower gently[(6.2±1.8) ng/L vs (6.4±1.9) ng/L] (P>0.05). Significant change of simvastatin treatment on SGRQ was only reflected in the symp-tom score [pre-post-treatment:39.6±10. 8 vs 32.3±11.6,P<0.05,respectively],while other observation items (SNOT-20,FEV1%,FEV1/FVC) changed not notably (P>0.05). No marked changes in inflammatory markers and quality of life scores,lung function were observed in control group (P>0.05). Conclusion Simvastatin may be as-sociated with the potential to alleviate systemic inflammation and relieve symptoms in COPD patients.     

辛伐他汀对慢性阻塞性肺疾病患者全身性炎症反应的影响

Objective To investigate the influence of simvastatin on inflammatory indices in nasal lavage,sputum and blood and clinical index in patients with chronic obstructive pulmonary diseases (COPD). Methods Thirty-seven stable COPD patients were randomly divided into simvastatin-treatment group (n=17),orally given simvastatin tablets for 4 weeks in addition to basic therapy,40 mg,qd) and control group (n=20),given usual med-ication). Total cell counts,percentage of leukocytes (N%) and levels of interleukin IL-8,IL-6 in nasal lavage and sputum at pre-post-treatment were compared;Serum C-reactive protein (CRP),total cholesterol (TC),low-density lipoprotein-cholesterol (LDL-C) as well as IL-8,IL-6 concentrations were measured,the variation of lung function,Sino-Nasal Outcome Test 20(SNOT-20) and St George's Respiratory Questionnaire(SGRQ) score were analyzed. Results After the treatment,the nasal lavage and sputum total cell counts,N%,IL-8 and IL-6 levels[nasal lavage: (0.7±0.3)×107/L,(41.1±10.9)%,(105.8±74.5) ng/L,(3.8±1.6) ng/L;sputum: (0.8±0.3)×109/L,(56.6±9.6) %,(2565.5±831.9) ng/L,(109.8±42.3) ng/L] dropped slightly in the simvastatin group com-pared with that at pretreatment [nasal lavage: (0.8±0.3)×107/L,(43.2±10.8) %,(107.6±86.3) ng/L,(4.1±1.9)ng/L;sputum: (0.8±0.3)×109/L,(58.1±9.3)% ,(2659.4±885.2) ng/L,(111.8±46.6) ng/L] (P>0.05) ;There were significant decreases in serum CRP [(4.3±3.7) mg/L vs (2.6±1.8) mg/L],IL-6 [(4.8±2.0)ng/L vs(4.7±1.9)ng/L] ,TC[(4.2±1.0) mmol/L vs(3.7±0.8)mmol/L] ,LDL-C[(2.4±0.5) mmol/L vs (2.2±0.5)mmol/L] (P>0.05) ;IL-8 concentrations in serum were lower gently[(6.2±1.8) ng/L vs (6.4±1.9) ng/L] (P>0.05). Significant change of simvastatin treatment on SGRQ was only reflected in the symp-tom score [pre-post-treatment:39.6±10. 8 vs 32.3±11.6,P<0.05,respectively],while other observation items (SNOT-20,FEV1%,FEV1/FVC) changed not notably (P>0.05). No marked changes in inflammatory markers and quality of life scores,lung function were observed in control group (P>0.05). Conclusion Simvastatin may be as-sociated with the potential to alleviate systemic inflammation and relieve symptoms in COPD patients.     

辛伐他汀对慢性阻塞性肺疾病患者全身性炎症反应的影响

Objective To investigate the influence of simvastatin on inflammatory indices in nasal lavage,sputum and blood and clinical index in patients with chronic obstructive pulmonary diseases (COPD). Methods Thirty-seven stable COPD patients were randomly divided into simvastatin-treatment group (n=17),orally given simvastatin tablets for 4 weeks in addition to basic therapy,40 mg,qd) and control group (n=20),given usual med-ication). Total cell counts,percentage of leukocytes (N%) and levels of interleukin IL-8,IL-6 in nasal lavage and sputum at pre-post-treatment were compared;Serum C-reactive protein (CRP),total cholesterol (TC),low-density lipoprotein-cholesterol (LDL-C) as well as IL-8,IL-6 concentrations were measured,the variation of lung function,Sino-Nasal Outcome Test 20(SNOT-20) and St George's Respiratory Questionnaire(SGRQ) score were analyzed. Results After the treatment,the nasal lavage and sputum total cell counts,N%,IL-8 and IL-6 levels[nasal lavage: (0.7±0.3)×107/L,(41.1±10.9)%,(105.8±74.5) ng/L,(3.8±1.6) ng/L;sputum: (0.8±0.3)×109/L,(56.6±9.6) %,(2565.5±831.9) ng/L,(109.8±42.3) ng/L] dropped slightly in the simvastatin group com-pared with that at pretreatment [nasal lavage: (0.8±0.3)×107/L,(43.2±10.8) %,(107.6±86.3) ng/L,(4.1±1.9)ng/L;sputum: (0.8±0.3)×109/L,(58.1±9.3)% ,(2659.4±885.2) ng/L,(111.8±46.6) ng/L] (P>0.05) ;There were significant decreases in serum CRP [(4.3±3.7) mg/L vs (2.6±1.8) mg/L],IL-6 [(4.8±2.0)ng/L vs(4.7±1.9)ng/L] ,TC[(4.2±1.0) mmol/L vs(3.7±0.8)mmol/L] ,LDL-C[(2.4±0.5) mmol/L vs (2.2±0.5)mmol/L] (P>0.05) ;IL-8 concentrations in serum were lower gently[(6.2±1.8) ng/L vs (6.4±1.9) ng/L] (P>0.05). Significant change of simvastatin treatment on SGRQ was only reflected in the symp-tom score [pre-post-treatment:39.6±10. 8 vs 32.3±11.6,P<0.05,respectively],while other observation items (SNOT-20,FEV1%,FEV1/FVC) changed not notably (P>0.05). No marked changes in inflammatory markers and quality of life scores,lung function were observed in control group (P>0.05). Conclusion Simvastatin may be as-sociated with the potential to alleviate systemic inflammation and relieve symptoms in COPD patients.     

辛伐他汀对慢性阻塞性肺疾病患者全身性炎症反应的影响

Objective To investigate the influence of simvastatin on inflammatory indices in nasal lavage,sputum and blood and clinical index in patients with chronic obstructive pulmonary diseases (COPD). Methods Thirty-seven stable COPD patients were randomly divided into simvastatin-treatment group (n=17),orally given simvastatin tablets for 4 weeks in addition to basic therapy,40 mg,qd) and control group (n=20),given usual med-ication). Total cell counts,percentage of leukocytes (N%) and levels of interleukin IL-8,IL-6 in nasal lavage and sputum at pre-post-treatment were compared;Serum C-reactive protein (CRP),total cholesterol (TC),low-density lipoprotein-cholesterol (LDL-C) as well as IL-8,IL-6 concentrations were measured,the variation of lung function,Sino-Nasal Outcome Test 20(SNOT-20) and St George's Respiratory Questionnaire(SGRQ) score were analyzed. Results After the treatment,the nasal lavage and sputum total cell counts,N%,IL-8 and IL-6 levels[nasal lavage: (0.7±0.3)×107/L,(41.1±10.9)%,(105.8±74.5) ng/L,(3.8±1.6) ng/L;sputum: (0.8±0.3)×109/L,(56.6±9.6) %,(2565.5±831.9) ng/L,(109.8±42.3) ng/L] dropped slightly in the simvastatin group com-pared with that at pretreatment [nasal lavage: (0.8±0.3)×107/L,(43.2±10.8) %,(107.6±86.3) ng/L,(4.1±1.9)ng/L;sputum: (0.8±0.3)×109/L,(58.1±9.3)% ,(2659.4±885.2) ng/L,(111.8±46.6) ng/L] (P>0.05) ;There were significant decreases in serum CRP [(4.3±3.7) mg/L vs (2.6±1.8) mg/L],IL-6 [(4.8±2.0)ng/L vs(4.7±1.9)ng/L] ,TC[(4.2±1.0) mmol/L vs(3.7±0.8)mmol/L] ,LDL-C[(2.4±0.5) mmol/L vs (2.2±0.5)mmol/L] (P>0.05) ;IL-8 concentrations in serum were lower gently[(6.2±1.8) ng/L vs (6.4±1.9) ng/L] (P>0.05). Significant change of simvastatin treatment on SGRQ was only reflected in the symp-tom score [pre-post-treatment:39.6±10. 8 vs 32.3±11.6,P<0.05,respectively],while other observation items (SNOT-20,FEV1%,FEV1/FVC) changed not notably (P>0.05). No marked changes in inflammatory markers and quality of life scores,lung function were observed in control group (P>0.05). Conclusion Simvastatin may be as-sociated with the potential to alleviate systemic inflammation and relieve symptoms in COPD patients.     

辛伐他汀对慢性阻塞性肺疾病患者全身性炎症反应的影响

Objective To investigate the influence of simvastatin on inflammatory indices in nasal lavage,sputum and blood and clinical index in patients with chronic obstructive pulmonary diseases (COPD). Methods Thirty-seven stable COPD patients were randomly divided into simvastatin-treatment group (n=17),orally given simvastatin tablets for 4 weeks in addition to basic therapy,40 mg,qd) and control group (n=20),given usual med-ication). Total cell counts,percentage of leukocytes (N%) and levels of interleukin IL-8,IL-6 in nasal lavage and sputum at pre-post-treatment were compared;Serum C-reactive protein (CRP),total cholesterol (TC),low-density lipoprotein-cholesterol (LDL-C) as well as IL-8,IL-6 concentrations were measured,the variation of lung function,Sino-Nasal Outcome Test 20(SNOT-20) and St George's Respiratory Questionnaire(SGRQ) score were analyzed. Results After the treatment,the nasal lavage and sputum total cell counts,N%,IL-8 and IL-6 levels[nasal lavage: (0.7±0.3)×107/L,(41.1±10.9)%,(105.8±74.5) ng/L,(3.8±1.6) ng/L;sputum: (0.8±0.3)×109/L,(56.6±9.6) %,(2565.5±831.9) ng/L,(109.8±42.3) ng/L] dropped slightly in the simvastatin group com-pared with that at pretreatment [nasal lavage: (0.8±0.3)×107/L,(43.2±10.8) %,(107.6±86.3) ng/L,(4.1±1.9)ng/L;sputum: (0.8±0.3)×109/L,(58.1±9.3)% ,(2659.4±885.2) ng/L,(111.8±46.6) ng/L] (P>0.05) ;There were significant decreases in serum CRP [(4.3±3.7) mg/L vs (2.6±1.8) mg/L],IL-6 [(4.8±2.0)ng/L vs(4.7±1.9)ng/L] ,TC[(4.2±1.0) mmol/L vs(3.7±0.8)mmol/L] ,LDL-C[(2.4±0.5) mmol/L vs (2.2±0.5)mmol/L] (P>0.05) ;IL-8 concentrations in serum were lower gently[(6.2±1.8) ng/L vs (6.4±1.9) ng/L] (P>0.05). Significant change of simvastatin treatment on SGRQ was only reflected in the symp-tom score [pre-post-treatment:39.6±10. 8 vs 32.3±11.6,P<0.05,respectively],while other observation items (SNOT-20,FEV1%,FEV1/FVC) changed not notably (P>0.05). No marked changes in inflammatory markers and quality of life scores,lung function were observed in control group (P>0.05). Conclusion Simvastatin may be as-sociated with the potential to alleviate systemic inflammation and relieve symptoms in COPD patients.     

辛伐他汀对慢性阻塞性肺疾病患者全身性炎症反应的影响

Objective To investigate the influence of simvastatin on inflammatory indices in nasal lavage,sputum and blood and clinical index in patients with chronic obstructive pulmonary diseases (COPD). Methods Thirty-seven stable COPD patients were randomly divided into simvastatin-treatment group (n=17),orally given simvastatin tablets for 4 weeks in addition to basic therapy,40 mg,qd) and control group (n=20),given usual med-ication). Total cell counts,percentage of leukocytes (N%) and levels of interleukin IL-8,IL-6 in nasal lavage and sputum at pre-post-treatment were compared;Serum C-reactive protein (CRP),total cholesterol (TC),low-density lipoprotein-cholesterol (LDL-C) as well as IL-8,IL-6 concentrations were measured,the variation of lung function,Sino-Nasal Outcome Test 20(SNOT-20) and St George's Respiratory Questionnaire(SGRQ) score were analyzed. Results After the treatment,the nasal lavage and sputum total cell counts,N%,IL-8 and IL-6 levels[nasal lavage: (0.7±0.3)×107/L,(41.1±10.9)%,(105.8±74.5) ng/L,(3.8±1.6) ng/L;sputum: (0.8±0.3)×109/L,(56.6±9.6) %,(2565.5±831.9) ng/L,(109.8±42.3) ng/L] dropped slightly in the simvastatin group com-pared with that at pretreatment [nasal lavage: (0.8±0.3)×107/L,(43.2±10.8) %,(107.6±86.3) ng/L,(4.1±1.9)ng/L;sputum: (0.8±0.3)×109/L,(58.1±9.3)% ,(2659.4±885.2) ng/L,(111.8±46.6) ng/L] (P>0.05) ;There were significant decreases in serum CRP [(4.3±3.7) mg/L vs (2.6±1.8) mg/L],IL-6 [(4.8±2.0)ng/L vs(4.7±1.9)ng/L] ,TC[(4.2±1.0) mmol/L vs(3.7±0.8)mmol/L] ,LDL-C[(2.4±0.5) mmol/L vs (2.2±0.5)mmol/L] (P>0.05) ;IL-8 concentrations in serum were lower gently[(6.2±1.8) ng/L vs (6.4±1.9) ng/L] (P>0.05). Significant change of simvastatin treatment on SGRQ was only reflected in the symp-tom score [pre-post-treatment:39.6±10. 8 vs 32.3±11.6,P<0.05,respectively],while other observation items (SNOT-20,FEV1%,FEV1/FVC) changed not notably (P>0.05). No marked changes in inflammatory markers and quality of life scores,lung function were observed in control group (P>0.05). Conclusion Simvastatin may be as-sociated with the potential to alleviate systemic inflammation and relieve symptoms in COPD patients.